Log in

Viking Therapeutics Stock Forecast, Price & News

-0.06 (-0.99 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $6.03
50-Day Range
MA: $6.92
52-Week Range
Now: $6.03
Volume1.20 million shs
Average Volume1.43 million shs
Market Capitalization$438.73 million
P/E RatioN/A
Dividend YieldN/A
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Read More
Viking Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.80 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:VKTX



Sales & Book Value

Annual SalesN/A
Book Value$3.83 per share


Net Income$-25,780,000.00


Market Cap$438.73 million
Next Earnings Date11/3/2020 (Estimated)
-0.06 (-0.99 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions

How has Viking Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Viking Therapeutics' stock was trading at $5.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VKTX shares have increased by 18.9% and is now trading at $6.03.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Viking Therapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Viking Therapeutics

When is Viking Therapeutics' next earnings date?

Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Viking Therapeutics

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics Inc (NASDAQ:VKTX) announced its quarterly earnings data on Wednesday, July, 29th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.01.
View Viking Therapeutics' earnings history

What price target have analysts set for VKTX?

11 equities research analysts have issued 12 month price objectives for Viking Therapeutics' stock. Their forecasts range from $12.00 to $25.00. On average, they expect Viking Therapeutics' share price to reach $16.33 in the next year. This suggests a possible upside of 170.9% from the stock's current price.
View analysts' price targets for Viking Therapeutics

Are investors shorting Viking Therapeutics?

Viking Therapeutics saw a decrease in short interest during the month of August. As of August 14th, there was short interest totaling 8,730,000 shares, a decrease of 17.6% from the July 30th total of 10,590,000 shares. Based on an average daily trading volume, of 1,340,000 shares, the short-interest ratio is currently 6.5 days. Approximately 12.3% of the shares of the company are sold short.
View Viking Therapeutics' Short Interest

Who are some of Viking Therapeutics' key competitors?

What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Verastem (VSTM), Advanced Micro Devices (AMD), Energy Transfer LP Unit (ET) and Inovio Pharmaceuticals (INO).

Who are Viking Therapeutics' key executives?

Viking Therapeutics' management team includes the following people:
  • Dr. Brian Lian, Pres, CEO & Director (Age 54, Pay $735k)
  • Mr. Gregory S. Zante, Sr. VP of Fin. (Age 49)
  • Mr. Michael Morneau, VP of Fin. & Admin. (Age 55)
  • Ms. Amy Broidrick, Sr. VP of Corp. Devel.
  • Ms. Marianne Mancini, Sr. VP of Clinical Operations

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager.

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (11.63%), Vanguard Group Inc. (4.66%), FMR LLC (2.61%), Goldman Sachs Group Inc. (0.79%), Raymond James & Associates (0.52%) and State of Wisconsin Investment Board (0.52%). Company insiders that own Viking Therapeutics stock include Ligand Pharmaceuticals Inc and Matthew W Foehr.
View institutional ownership trends for Viking Therapeutics

Which major investors are selling Viking Therapeutics stock?

VKTX stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, FMR LLC, SG Americas Securities LLC, Bailard Inc., UBS Group AG, Alps Advisors Inc., Creative Planning, and Exane Derivatives. Company insiders that have sold Viking Therapeutics company stock in the last year include Ligand Pharmaceuticals Inc, and Matthew W Foehr.
View insider buying and selling activity for Viking Therapeutics

Which major investors are buying Viking Therapeutics stock?

VKTX stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Raymond James & Associates, WINTON GROUP Ltd, Two Sigma Advisers LP, Raymond James Financial Services Advisors Inc., Rafferty Asset Management LLC, Vanguard Group Inc., and Swiss National Bank.
View insider buying and selling activity for Viking Therapeutics

How do I buy shares of Viking Therapeutics?

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Viking Therapeutics' stock price today?

One share of VKTX stock can currently be purchased for approximately $6.03.

How big of a company is Viking Therapeutics?

Viking Therapeutics has a market capitalization of $438.73 million. The biotechnology company earns $-25,780,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Viking Therapeutics employs 17 workers across the globe.

What is Viking Therapeutics' official website?

The official website for Viking Therapeutics is www.vikingtherapeutics.com.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.